Exhibit 99.1

        PharmaFrontiers Corp. Reconstitutes Its Audit Committee

    THE WOODLANDS, Texas--(BUSINESS WIRE)--Nov. 1,
2005--PharmaFrontiers Corp. (OTCBB:PFTR), a company involved in the
development and commercialization of cell therapies, announced today
that Brooks Boveroux, Chairman of the Board of Directors of the
Company, has been unanimously elected to chairman of the audit
committee, effective immediately. Mr. Boveroux, age 62, is replacing
Brian Rodriguez, who has resigned from both the board of directors and
his position as chairman of the audit committee.
    "I am pleased to be taking on the role as chairman of the audit
committee at this important time," said Mr. Boveroux. "My fellow Board
members and I thank Brian for helping PharmaFrontiers achieve a
successful reverse merger and wish him well in his future endeavors.
This is an exciting time as we prepare to implement our upcoming Phase
IIb trials for Tovaxin(TM) in Multiple Sclerosis. We are encouraged
about the power of our technology to treat this devastating disease."
    Mr. Boveroux's career has spanned over two decades of senior level
financial positions with public and private companies both in the
research stage and those marketing approved products in the health
care industry. His last position was chief financial officer of Imcor
Pharmaceutical Co., a specialty pharmaceutical company, from which he
retired in 2004. Mr. Boveroux has held the post of vice president of
finance for several prominent biotechnology companies including
Biogen, Inc., ImClone Systems, Inc. and The Liposome Company, Inc.
    David McWilliams, chief executive officer of PharmaFrontiers
Corp., commented, "Mr. Boveroux's public company financial experience
will be a key asset to our audit committee. This is the ideal time in
the Company's development to appoint an audit committee chairman who
possesses a wealth of financial knowledge and experience."

    About PharmaFrontiers Corp.

    PharmaFrontiers' strategy is to develop and commercialize cell
therapies to treat several major disease areas such as cardiac and
pancreatic conditions and Multiple Sclerosis. PharmaFrontiers owns
patented and proprietary individualized cell therapies that are in FDA
Phase I/II human dose ranging clinical trials to evaluate their safety
and effectiveness in treating MS. The company also holds the exclusive
worldwide license from the University of Chicago, through its prime
contractor relationship with Argonne National Laboratory, for patents
relating to the use of adult pluripotent stem cells derived from
patients' own circulating blood.

    Safe Harbor Statement

    This press release contains "forward-looking statements,"
including statements about PharmaFrontiers' growth and future
operating results, discovery and development of products, strategic
alliances and intellectual property, as well as other matters that are
not historical facts or information. These forward-looking statements
are based on management's current assumptions and expectations and
involve risks, uncertainties and other important factors, specifically
including those relating to PharmaFrontiers' ability to obtain
additional funding, develop its stem cell technologies, achieve its
operational objectives, and obtain patent protection for its
discoveries, that may cause PharmaFrontiers' actual results to be
materially different from any future results expressed or implied by
such forward-looking statements. PharmaFrontiers undertakes no
obligation to update or revise any such forward-looking statements,
whether as a result of new information, future events or otherwise.



    CONTACT: PharmaFrontiers Corp., The Woodlands
             C. William Rouse, 281-775-0608
             brouse@pharmafrontierscorp.com
             or
             Investor Relations Contacts:
             Lippert/Heilshorn & Associates
             Kim Sutton Golodetz, 212-838-3777
             kgolodetz@lhai.com
             or
             Bruce Voss, 310-691-7100
             bvoss@lhai.com
             or
             Media Relations Contact:
             Lippert/Heilshorn & Associates
             Mark Stuart, 310-691-7100
             mstuart@lhai.com